Glioblastoma multiforme (GBM) is one of the most common brain malignancies and has a very poor prognosis. Recent evidence suggests that the presence of cancer stem cells (CSC) in GBM and the rare CSC subpopulation that is resistant to chemotherapy may be responsible for the treatment failure and unfavorable prognosis of GBM. A garlic-derived compound, Z-ajoene, has shown a range of biological activities, including anti-proliferative effects on several cancers. Here, we demonstrated for the first time that Z-ajoene specifically inhibits the growth of the GBM CSC population. CSC sphere-forming inhibition was achieved at a concentration that did not exhibit a cytotoxic effect in regular cell culture conditions. The specificity of this inhibitory effect on the CSC population was confirmed by detecting CSC cell surface marker CD133 expression and biochemical marker ALDH activity. In addition, stem cell-related mRNA profiling and real-time PCR revealed the differential expression of CSC-specific genes, including Notch, Wnt, and Hedgehog, upon treatment with Z-ajoene. A proteomic approach, i.e., reverse-phase protein array (RPPA) and Western blot analysis, showed decreased SMAD4, p-AKT, 14.3.3 and FOXO3A expression. The protein interaction map (http://string-db.org/) of the identified molecules suggested that the AKT, ERK/p38 and TGFβ signaling pathways are key mediators of Z-ajoene's action, which affects the transcriptional network that includes FOXO3A. These biological and bioinformatic analyses collectively demonstrate that Z-ajoene is a potential candidate for the treatment of GBM by specifically targeting GBM CSCs. We also show how this systemic approach strengthens the identification of new therapeutic agents that target CSCs.

Many aminodihydroquinoline compounds have been studied to determine their cytotoxicity to cancer cells. However, anti-cancer stem cells (CSCs) activity of aminodihydroquinoline has not been tested in spite that CSC is believed to do an important roles in chemotherapy resistance and recurrence. The CSC selective targeting activities of 10 recently synthesized 2-aminodihydroquinoline analogs were examined on CSCs and bulk culture of a glioblastoma cell line. A diethylaminopropyl substituted aminodihydroquinoline, 5h, showed a strong anti-CSC effect and general cytotoxicity. However, a benzyl substituted aminodihydroquinoline, 5i, displayed the most effective anti-CSC effect, with no or small significant cytotoxic effect in bulk culture conditions. While 5h temporarily enhanced CSC marker-positive cells and eventually suppressed the CSC population, which is similar to other cytotoxic anticancer reagents reported, 5i selectively eliminated CSC marker-positive cells based on fluorescence activated cell sorter (FACS) analysis. 5h also temporarily activated some genes associated with signaling required for CSC, while 5i selectively suppressed these genes supporting that the differential effects are resulted from different molecular responses. In addition, the selective CSC effect is also found against a colon cancer cell line. Collectively, we suggest that these two novel aminodihydroquinoline compounds possess novel anti-CSC effects in colon and brain tumor derived cell lines probably through independent pathways. Key words 2-aminodihydroquinoline; cancer stem cell; selective targeting More than 50 years ago, it was noted that heterogeneous cell populations may exist in a tumor, and that in vivo tumor intimating cells are only a small portion of the tumor.1,2) These tumor initiating cells have been isolated from most types of tumors. These cells are now referred to as cancer stem cells (CSC) because they share many characteristics with tissue stem cells and mediate stem-like roles in cancer.2) Due to the critical roles of CSCs in chemotherapy and radiotherapy resistance, many pre-clinical studies and clinical trials have been undertaken to develop new strategies to eliminate CSCs. 3)Several novel compounds have been developed and are under evaluation as CSC therapeutics (reviewed in Jung et al. 3)). The majority of currently used clinical anti-cancer reagents target the fast proliferation effect of cancer cells. Most of those chemo-therapeutic agents have been developed based on their cytotoxic effect since the first chemotherapeutic agent, aminopterin, was used for leukemia in 1947. 4,5) Since then, hundreds of thousands of chemicals have been developed as cancer therapies to target cancer cell cycle. However, acquired resistance is the most serious problem for virtually all currently used chemotherapeutic agents. Therefore, to overcome chemo-resistance, anti-CSC agents need to be urgently developed. Aminodihydroquinoline analogs have attracted attention in drug discovery due to their variable range of biological act...